Pub Date : 2025-03-01DOI: 10.1016/j.remn.2024.500083
K. Quintero , E. Vila , L. Ferrer-Mileo , D. Vas , Maria J. Ribal , M. Garcia-Herreros , N. Navarro , M. Tormo-Ratera , C. Aversa , A. Vilaseca , A. Farré-Melero , D. Fuster , P. Paredes , grupo de Medicina Nuclear Clínic Barcelona (MNCB)
Objective
To evaluate the correlation between response assessment measured by PET/CT with [18F] F-fluorocholine (Choline PET/CT) and serum levels of PSA in patients with prostate cancer under antiandrogenic treatment.
Methodology
A retrospective study included patients with CRPC and CSPC treated with enzalutamide, abiraterone, or apalutamide between June 2018 and July 2021, who underwent baseline and a follow-up Choline PET/CT. The difference in maximum SUVmax (ΔSUV) between both studies and the PSA value before and at follow-up were recorded. The response to treatment was compared by PSA vs. PET, assessing their association, agreement, and correlation.
Results
Thirty patients were included (median age 74 years, range 68-78), 12 with CSPC and 18 with CRPC; 22 had nodal disease, and 15 had active bone disease. The average time between pre-treatment and follow-up PET/CT was 11 months (range 3.5-23).
Patients with extra-nodal metastatic disease at the beginning of treatment showed a higher correlation between PSA and ΔSUV (OR 4.375). In patients with bone disease at the start of treatment, 80% were classified as non-responders on PET response assessment, while only 40% were non-responders by PSA.
The correlation between PET and PSA was mild (Kendall's tau_b 0.26), and the classification into Responders/Non-responders had only slight agreement (Cohen's kappa 0.30).
Conclusion
Choline PET/CT shows low concordance with the PSA values obtained during the follow-up of response to anti-androgen therapy, especially in patients with bone involvement.
{"title":"Utilidad de la PET/TC con [18F]F-fluorocolina en la valoración de respuesta a la terapia antiandrogénica en pacientes con cáncer de próstata","authors":"K. Quintero , E. Vila , L. Ferrer-Mileo , D. Vas , Maria J. Ribal , M. Garcia-Herreros , N. Navarro , M. Tormo-Ratera , C. Aversa , A. Vilaseca , A. Farré-Melero , D. Fuster , P. Paredes , grupo de Medicina Nuclear Clínic Barcelona (MNCB)","doi":"10.1016/j.remn.2024.500083","DOIUrl":"10.1016/j.remn.2024.500083","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the correlation between response assessment measured by PET/CT with [<sup>18</sup>F] F-fluorocholine (Choline PET/CT) and serum levels of PSA in patients with prostate cancer under antiandrogenic treatment.</div></div><div><h3>Methodology</h3><div>A retrospective study included patients with CRPC and CSPC treated with enzalutamide, abiraterone, or apalutamide between June 2018 and July 2021, who underwent baseline and a follow-up Choline PET/CT. The difference in maximum SUVmax (ΔSUV) between both studies and the PSA value before and at follow-up were recorded. The response to treatment was compared by PSA vs. PET, assessing their association, agreement, and correlation.</div></div><div><h3>Results</h3><div>Thirty patients were included (median age 74 years, range 68-78), 12 with CSPC and 18 with CRPC; 22 had nodal disease, and 15 had active bone disease. The average time between pre-treatment and follow-up PET/CT was 11 months (range 3.5-23).</div><div>Patients with extra-nodal metastatic disease at the beginning of treatment showed a higher correlation between PSA and ΔSUV (OR 4.375). In patients with bone disease at the start of treatment, 80% were classified as non-responders on PET response assessment, while only 40% were non-responders by PSA.</div><div>The correlation between PET and PSA was mild <em>(Kendall's tau_b</em> 0.26), and the classification into Responders/Non-responders had only slight agreement (<em>Cohen's kappa</em> 0.30).</div></div><div><h3>Conclusion</h3><div>Choline PET/CT shows low concordance with the PSA values obtained during the follow-up of response to anti-androgen therapy, especially in patients with bone involvement.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 2","pages":"Article 500083"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143510917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01DOI: 10.1016/j.remn.2024.500071
M. Cózar Santiago , J. García Garzón , A. Esteban Hurtado , J. Pastor Peiro , J. Ferrer Rebolleda
Objective
To assess the clinical value of [18F]F-PSMA negative PET/CT, in patients diagnosed with prostate cancer treated with prostatectomy with elevated PSA less than 1 ng/mL, on the outcome of salvage radiotherapy.
Method
We prospectively included 98 patients diagnosed with prostate cancer treated with prostatectomy with biochemical recurrence [mean PSA 0.51 ng/mL (range 0.17-1,0 ng/mL)] who were referred for an [18F]F-PSMA-PET/CT study.
The [18F]F-PSMA-PET/CT scan was negative in 53/98 patients (54.09%). Differences were analysed between those patients who were or were not candidates for pelvic salvage radiotherapy (PSRT) decided upon multidisciplinary committee and patient consent, with a minimum follow-up time for 1 year. Response to treatment was defined as a 50% reduction in PSA levels. Recurrence was ascertained upon clinical, analytical and imaging follow-up outcomes.
Results
54.7% (29/53) of the patients with a negative [18F]F-PSMA-PET/CT underwent PSRT. Of these, 93.1% (27/29) patients demonstrated response to treatment (PSMA false negatives). The remaining two patients showed fluctuating PSA levels without detecting disease on the [18F]F-PSMA-PET/CT follow-up study.
45.3% (24/53) of patients with negative [18F]F-PSMA-PET/CT did not undergo PSRT. Of these, progressive PSA elevation was observed in 62.5% (15/24) (PSMA false negatives), localising recurrence on the [18F]F-PSMA-PET/CT follow-up study in 4 patients. The remaining 9 patients (37.5%) showed fluctuating PSA levels without detecting disease on the [18F]F-PSMA-PET/CT follow-up study.
Our series confirmed 42 (42.85%) [18F]F-PSMA-PET/CT false negatives cases.
Conclusion
Patients diagnosed with prostate cancer with post-prostatectomy biochemical recurrence and a negative [18F]F-PSMA-PET/CT study are likely to benefit from pelvic salvage radiotherapy, with response seen in 93.1% of our cases.
{"title":"Valor clínico de un PET/TC con [18F]F-PSMA negativo en pacientes diagnosticados de cáncer de próstata tratados con prostatectomía con elevación del PSA, inferior a 1 ng/ml, en los resultados de la radioterapia de rescate","authors":"M. Cózar Santiago , J. García Garzón , A. Esteban Hurtado , J. Pastor Peiro , J. Ferrer Rebolleda","doi":"10.1016/j.remn.2024.500071","DOIUrl":"10.1016/j.remn.2024.500071","url":null,"abstract":"<div><h3>Objective</h3><div>To assess the clinical value of [<sup>18</sup>F]F-PSMA negative PET/CT, in patients diagnosed with prostate cancer treated with prostatectomy with elevated PSA less than 1<!--> <!-->ng/mL, on the outcome of salvage radiotherapy.</div></div><div><h3>Method</h3><div>We prospectively included 98 patients diagnosed with prostate cancer treated with prostatectomy with biochemical recurrence [mean PSA 0.51<!--> <!-->ng/mL (range 0.17-1,0<!--> <!-->ng/mL)] who were referred for an [<sup>18</sup>F]F-PSMA-PET/CT study.</div><div>The [<sup>18</sup>F]F-PSMA-PET/CT scan was negative in 53/98 patients (54.09%). Differences were analysed between those patients who were or were not candidates for pelvic salvage radiotherapy (PSRT) decided upon multidisciplinary committee and patient consent, with a minimum follow-up time for 1<!--> <!-->year. Response to treatment was defined as a 50% reduction in PSA levels. Recurrence was ascertained upon clinical, analytical and imaging follow-up outcomes.</div></div><div><h3>Results</h3><div>54.7% (29/53) of the patients with a negative [<sup>18</sup>F]F-PSMA-PET/CT underwent PSRT. Of these, 93.1% (27/29) patients demonstrated response to treatment (PSMA false negatives). The remaining two patients showed fluctuating PSA levels without detecting disease on the [<sup>18</sup>F]F-PSMA-PET/CT follow-up study.</div><div>45.3% (24/53) of patients with negative [<sup>18</sup>F]F-PSMA-PET/CT did not undergo PSRT. Of these, progressive PSA elevation was observed in 62.5% (15/24) (PSMA false negatives), localising recurrence on the [<sup>18</sup>F]F-PSMA-PET/CT follow-up study in 4 patients. The remaining 9 patients (37.5%) showed fluctuating PSA levels without detecting disease on the [<sup>18</sup>F]F-PSMA-PET/CT follow-up study.</div><div>Our series confirmed 42 (42.85%) [<sup>18</sup>F]F-PSMA-PET/CT false negatives cases.</div></div><div><h3>Conclusion</h3><div>Patients diagnosed with prostate cancer with post-prostatectomy biochemical recurrence and a negative [<sup>18</sup>F]F-PSMA-PET/CT study are likely to benefit from pelvic salvage radiotherapy, with response seen in 93.1% of our cases.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 2","pages":"Article 500071"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143510918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01DOI: 10.1016/j.remn.2024.500069
L. Rodríguez-Díaz , E. García , C. de Guirior , R. Salvador , J. Ribera-Perianes , S. Vidal-Sicart
{"title":"Técnica de marcaje con semilla radiactiva de 125-I en endometriosis inguinal","authors":"L. Rodríguez-Díaz , E. García , C. de Guirior , R. Salvador , J. Ribera-Perianes , S. Vidal-Sicart","doi":"10.1016/j.remn.2024.500069","DOIUrl":"10.1016/j.remn.2024.500069","url":null,"abstract":"","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 2","pages":"Article 500069"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143511175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-15DOI: 10.1016/j.remn.2025.500121
R. Luo, W. Zhang, A. Kuang, Y. Li
{"title":"Características de imagen poco comunes de la osteomielitis multifocal recurrente crónica en adultos en PET/CT","authors":"R. Luo, W. Zhang, A. Kuang, Y. Li","doi":"10.1016/j.remn.2025.500121","DOIUrl":"10.1016/j.remn.2025.500121","url":null,"abstract":"","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 3","pages":"Article 500121"},"PeriodicalIF":1.6,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143868720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-12DOI: 10.1016/j.remn.2024.500085
G. Kara Gedik , A. Volkan Çelik , M.U. Yalçın , M. Koplay , F. Yılmaz , H. Önner
<div><h3>Introduction and objectives</h3><div>Tissue attenuation reduces the specificity of the myocardial perfusion imaging single photon emission tomography (SPECT), which leads reduced diagnostic accuracy. The aim of this study is to compare performances of non-attenuation corrected (NAC), computed tomography based-attenuation corrected (AC) and prone images for qualitative and semi-quantitative analysis of myocardial perfusion SPECT in diagnosis of coronary artery disease (CAD).</div></div><div><h3>Materials and methods</h3><div>Eighty six patients in whom NAC, AC and prone images were obtained with SPECT, and whose coronary angiography/CT coronary angiography was completed within 3 months, were retrospectively studied. Myocardial perfusion scintigraphy was performed using SPECT/CT dual-headed gamma camera. Images were evaluated qualitatively and semi-quantitatively using 20-segment model. Analyzes of global myocardium and LAD, RCA, Cx vascular areas as regional analysis were performed. In qualitative evaluation, if SPECT study was abnormal, relevant coronary artery area was recorded. Quantitative Perfusion SPECT (QPS) program was used in semi-quantitative analysis; Summed Stress Score (SSS)<!--> <!-->≥<!--> <!-->4 was accepted for presence of CAD in per-patient analysis. In regional analysis SSS<!--> <!-->≥<!--> <!-->2 was taken into account. Coronary angiography/CT coronary angiography was used as gold standard. Threshold value was determined as ≥<!--> <!-->50% and above luminal diameter narrowing. While AC and NAC methods were compared for per-patient analysis and each vascular area; 3<!--> <!-->imaging methods including prone acquisition, were compared for the RCA area. Diagnostic performances of the methods were evaluated by comparing the areas under the curve with ROC analysis.</div></div><div><h3>Results</h3><div>In visual evaluation, sensitivity of AC was significantly lower than NAC in analyzes of per-patient, RCA and Cx areas (global 76.92% vs 86.15%, RCA 60.87% vs 82.61%, Cx 58.97% vs 69.23%, respectively; <em>P</em> <!--><<!--> <!-->.05). Sensitivity of prone imaging was significantly higher than AC in analysis of the RCA area (76.09% vs 60.87%, respectively; <em>P</em> <!--><<!--> <!-->.05) Specificity values were higher in analyzes of global, RCA and Cx areas in AC than in NAC method; this difference was significant in RCA and Cx areas (RCA 70% vs 42.50%, Cx 85.11% vs 70.21%, respectively; <em>P</em> <!--><<!--> <!-->.05). In semi-quantitative evaluation, AC and NAC had similar sensitivity and specificity in global and regional analyzes; in RCA area, no significant difference was detected between the 3<!--> <!-->methods. In ROC analysis, no significant difference was detected between methods in per-patient and regional analyzes both in visual and semi-quantitative evaluation.</div></div><div><h3>Conclusions</h3><div>CT-based attenuation correction increases specificity, but reduces sensitivity in the diagnosis of CAD in
问题衰减降低了心肌灌注成像单光子发射断层扫描（SPECT）的特异性，导致诊断准确性降低。本研究的目的是比较非衰减校正（NAC）、基于计算机断层扫描的衰减校正（AC）和倾向图像在定性和半定量分析心肌灌注SPECT诊断冠状动脉疾病（CAD）中的表现。材料与方法回顾性分析66例在3个月内完成冠状动脉造影/CT冠状动脉造影并经SPECT获得NAC、AC及俯卧位图像的患者。采用SPECT/CT双头伽马照相机进行心肌灌注显像。采用20段模型对图像进行定性和半定量评价。局部分析整体心肌及LAD、RCA、Cx血管区。定性评价时，如SPECT显像异常，记录相关冠状动脉面积。半定量分析采用定量灌注SPECT （QPS）程序；在每例患者分析中，接受压力总分(SSS)≥4作为存在CAD的标准。在区域分析中，考虑SSS≥2。冠状动脉造影/CT冠状动脉造影为金标准。阈值确定为≥50%及以上的管腔直径变窄。而AC和NAC方法在每个患者和每个血管区域的分析比较；比较了包括俯卧采集在内的3种成像方法对RCA区域的成像效果。通过曲线下面积与ROC分析的比较，评价各方法的诊断效果。结果在目视评价中，AC对单个患者、RCA和Cx区域的敏感性显著低于NAC (global 76.92% vs 86.15%, RCA 60.87% vs 82.61%, Cx 58.97% vs 69.23%)；P & lt;. 05)。俯卧位成像对RCA区域的敏感度显著高于AC（分别为76.09%和60.87%）；P & lt;0.05) AC法的全局、RCA和Cx区特异性值高于NAC法；RCA和Cx区差异显著(RCA分别为70% vs 42.50%， Cx为85.11% vs 70.21%；P & lt;. 05)。在半定量评价中，AC和NAC在全局和区域分析中具有相似的敏感性和特异性；在RCA区，3种方法间差异无统计学意义。在ROC分析中，在目测和半定量评估中，个体分析和区域分析的方法没有发现显著差异。结论基于ct的衰减校正增加了特异性，但降低了RCA和Cx局部区域诊断CAD的敏感性。俯卧位成像仍然是评估RCA区域的重要手段。
{"title":"Comparación de los rendimientos diagnósticos de la gammagrafía de perfusión miocárdica SPECT corregida por atenuación por TC y corregida sin atenuación en la enfermedad de las arterias coronarias","authors":"G. Kara Gedik , A. Volkan Çelik , M.U. Yalçın , M. Koplay , F. Yılmaz , H. Önner","doi":"10.1016/j.remn.2024.500085","DOIUrl":"10.1016/j.remn.2024.500085","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Tissue attenuation reduces the specificity of the myocardial perfusion imaging single photon emission tomography (SPECT), which leads reduced diagnostic accuracy. The aim of this study is to compare performances of non-attenuation corrected (NAC), computed tomography based-attenuation corrected (AC) and prone images for qualitative and semi-quantitative analysis of myocardial perfusion SPECT in diagnosis of coronary artery disease (CAD).</div></div><div><h3>Materials and methods</h3><div>Eighty six patients in whom NAC, AC and prone images were obtained with SPECT, and whose coronary angiography/CT coronary angiography was completed within 3 months, were retrospectively studied. Myocardial perfusion scintigraphy was performed using SPECT/CT dual-headed gamma camera. Images were evaluated qualitatively and semi-quantitatively using 20-segment model. Analyzes of global myocardium and LAD, RCA, Cx vascular areas as regional analysis were performed. In qualitative evaluation, if SPECT study was abnormal, relevant coronary artery area was recorded. Quantitative Perfusion SPECT (QPS) program was used in semi-quantitative analysis; Summed Stress Score (SSS)<!--> <!-->≥<!--> <!-->4 was accepted for presence of CAD in per-patient analysis. In regional analysis SSS<!--> <!-->≥<!--> <!-->2 was taken into account. Coronary angiography/CT coronary angiography was used as gold standard. Threshold value was determined as ≥<!--> <!-->50% and above luminal diameter narrowing. While AC and NAC methods were compared for per-patient analysis and each vascular area; 3<!--> <!-->imaging methods including prone acquisition, were compared for the RCA area. Diagnostic performances of the methods were evaluated by comparing the areas under the curve with ROC analysis.</div></div><div><h3>Results</h3><div>In visual evaluation, sensitivity of AC was significantly lower than NAC in analyzes of per-patient, RCA and Cx areas (global 76.92% vs 86.15%, RCA 60.87% vs 82.61%, Cx 58.97% vs 69.23%, respectively; <em>P</em> <!--><<!--> <!-->.05). Sensitivity of prone imaging was significantly higher than AC in analysis of the RCA area (76.09% vs 60.87%, respectively; <em>P</em> <!--><<!--> <!-->.05) Specificity values were higher in analyzes of global, RCA and Cx areas in AC than in NAC method; this difference was significant in RCA and Cx areas (RCA 70% vs 42.50%, Cx 85.11% vs 70.21%, respectively; <em>P</em> <!--><<!--> <!-->.05). In semi-quantitative evaluation, AC and NAC had similar sensitivity and specificity in global and regional analyzes; in RCA area, no significant difference was detected between the 3<!--> <!-->methods. In ROC analysis, no significant difference was detected between methods in per-patient and regional analyzes both in visual and semi-quantitative evaluation.</div></div><div><h3>Conclusions</h3><div>CT-based attenuation correction increases specificity, but reduces sensitivity in the diagnosis of CAD in","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 3","pages":"Article 500085"},"PeriodicalIF":1.6,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143868615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-12DOI: 10.1016/j.remn.2024.500086
S. Malhotra , A. Peix , C. Gutierrez-Villamil , M. Bazan , R. Giubbini , C. Cueva , E. Estrada , D. Paez
Latin America is one of the regions in the world with the highest levels of overweight, dyslipidemia, and diabetes mellitus, which, together with smoking and high blood pressure, are common risk factors for cardiovascular and oncological diseases. Chemotherapy (CT) and radiotherapy (RT) have become two of the mainstays of treatment for several types of cancer. One of the most worrisome side effects generated by CT and RT is cardiotoxicity. There are several imaging techniques in cardiology that can inform the presence of underlying disease, but they differ in their availability and access to the masses, their accuracy and repeatability, all of which are important determinants of the applicability of these techniques in routine clinical practice. Thus, it is mandatory to promote a clinically effective and a cost-effective multimodality approach for risk stratification, diagnosis and management of cardiovascular diseases in oncologic patients. The purpose of this review is to inform cardiologists, oncologists, cardio-oncologists and imaging cardiologists on the cardiac imaging modalities that can be applied in patients with cancer, the differences among imaging techniques and recommendations on how to apply them in Latin America.
{"title":"Aplicación práctica de la imagen multimodal en la cardio-oncología en América Latina","authors":"S. Malhotra , A. Peix , C. Gutierrez-Villamil , M. Bazan , R. Giubbini , C. Cueva , E. Estrada , D. Paez","doi":"10.1016/j.remn.2024.500086","DOIUrl":"10.1016/j.remn.2024.500086","url":null,"abstract":"<div><div>Latin America is one of the regions in the world with the highest levels of overweight, dyslipidemia, and diabetes mellitus, which, together with smoking and high blood pressure, are common risk factors for cardiovascular and oncological diseases. Chemotherapy (CT) and radiotherapy (RT) have become two of the mainstays of treatment for several types of cancer. One of the most worrisome side effects generated by CT and RT is cardiotoxicity. There are several imaging techniques in cardiology that can inform the presence of underlying disease, but they differ in their availability and access to the masses, their accuracy and repeatability, all of which are important determinants of the applicability of these techniques in routine clinical practice. Thus, it is mandatory to promote a clinically effective and a cost-effective multimodality approach for risk stratification, diagnosis and management of cardiovascular diseases in oncologic patients. The purpose of this review is to inform cardiologists, oncologists, cardio-oncologists and imaging cardiologists on the cardiac imaging modalities that can be applied in patients with cancer, the differences among imaging techniques and recommendations on how to apply them in Latin America.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 3","pages":"Article 500086"},"PeriodicalIF":1.6,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143869301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-05DOI: 10.1016/j.remn.2025.500120
A. Bota-Bota, M. Pombo-López, I. Martínez-Rodríguez, F. Gómez-de la Fuente, J. Jiménez-Bonilla, R. Quirce
{"title":"Metástasis única de melanoma maligno cutáneo en la vesícula biliar detectada con 18F-FDG PET/TC","authors":"A. Bota-Bota, M. Pombo-López, I. Martínez-Rodríguez, F. Gómez-de la Fuente, J. Jiménez-Bonilla, R. Quirce","doi":"10.1016/j.remn.2025.500120","DOIUrl":"10.1016/j.remn.2025.500120","url":null,"abstract":"","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 3","pages":"Article 500120"},"PeriodicalIF":1.6,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143868719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-18DOI: 10.1016/j.remn.2024.500084
D.A. López-Mora , L. Lozano Murgas , M. Hervas Pujol , A.A. Rodríguez Revuelto
{"title":"Patrón característico en la PET/TC con [18F]FDG en la encefalitis antirreceptor NMDA","authors":"D.A. López-Mora , L. Lozano Murgas , M. Hervas Pujol , A.A. Rodríguez Revuelto","doi":"10.1016/j.remn.2024.500084","DOIUrl":"10.1016/j.remn.2024.500084","url":null,"abstract":"","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 5","pages":"Article 500084"},"PeriodicalIF":1.6,"publicationDate":"2025-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144908669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号